Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · IEX Real-Time Price · USD
47.82
+0.49 (1.04%)
At close: Jul 19, 2024, 4:00 PM
49.56
+1.74 (3.64%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
Ionis Pharmaceuticals Employees
Ionis Pharmaceuticals had 927 employees as of February 15, 2024. The number of employees increased by 131 or 16.46% compared to the previous year.
Employees
927
Change (1Y)
131
Growth (1Y)
16.46%
Revenue / Employee
$837,778
Profits / Employee
-$415,066
Market Cap
6.98B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Feb 15, 2024 | 927 | 131 | 16.46% |
Feb 16, 2023 | 796 | 136 | 20.61% |
Feb 16, 2022 | 660 | -97 | -12.81% |
Feb 18, 2021 | 757 | -60 | -7.34% |
Feb 20, 2020 | 817 | 80 | 10.85% |
Feb 20, 2019 | 737 | 190 | 34.73% |
Feb 20, 2018 | 547 | 112 | 25.75% |
Feb 21, 2017 | 435 | 7 | 1.64% |
Feb 19, 2016 | 428 | 38 | 9.74% |
Feb 17, 2015 | 390 | 86 | 28.29% |
Feb 17, 2014 | 304 | 16 | 5.56% |
Feb 11, 2013 | 288 | 7 | 2.49% |
Feb 13, 2012 | 281 | 11 | 4.07% |
Feb 14, 2011 | 270 | 20 | 8.00% |
Feb 10, 2010 | 250 | -50 | -16.67% |
Feb 10, 2009 | 300 | 0 | - |
Mar 1, 2008 | 300 | 26 | 9.49% |
Mar 5, 2007 | 274 | 16 | 6.20% |
Mar 3, 2006 | 258 | -45 | -14.85% |
Mar 3, 2005 | 303 | -154 | -33.70% |
Mar 3, 2004 | 457 | -66 | -12.62% |
Feb 28, 2003 | 523 | 89 | 20.51% |
Feb 28, 2002 | 434 | 131 | 43.23% |
Jan 31, 2001 | 303 | -49 | -13.92% |
Feb 25, 2000 | 352 | 6 | 1.73% |
Feb 26, 1999 | 346 | 8 | 2.37% |
Feb 27, 1998 | 338 | 51 | 17.77% |
Jan 31, 1997 | 287 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
The Ensign Group | 35,300 |
Penumbra | 4,200 |
Jazz Pharmaceuticals | 2,800 |
Tempus AI | 1,952 |
Repligen | 1,783 |
Exelixis | 1,310 |
Ascendis Pharma | 879 |
Blueprint Medicines | 655 |
IONS News
- 56 minutes ago - Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome - PRNewsWire
- 2 days ago - Ionis to hold second quarter 2024 financial results webcast - PRNewsWire
- 4 days ago - Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease - PRNewsWire
- 14 days ago - Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome - PRNewsWire
- 27 days ago - Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed - PRNewsWire
- 4 weeks ago - M&A Is Back. 4 Stocks That Could Be Targets. - Barrons
- 4 weeks ago - Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema - PRNewsWire
- 4 weeks ago - Ionis to present at TD Cowen Genetic Medicines & RNA Summit - PRNewsWire